RLMD NASDAQ
Relmada Therapeutics, Inc.
1W: -6.0%
1M: -20.7%
3M: -43.1%
YTD: -17.6%
1Y: +66.7%
3Y: +357.1%
5Y: -38.1%
$3.60
-0.06 (-1.64%)
Weekly Expected Move ±9.0%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (41)
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Relmada (RLMD) Q2 2026 Earnings Call Transcript
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada plans NDV-01 IND by end of 2026 as cash runway extends through 2029
ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short Interest
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Hewlett Packard Enterprise Posts Blowout Q2 Earnings, Joins Marvell Technology And Other Big Stocks Moving Higher In Tuesday's Session
Relmada targets mid-2026 Phase 3 RESCUE start backed by $234M cash runway through 2029
Earnings Scheduled For May 12, 2026
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $12.00 Consensus Target Price from Analysts
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest
Relmada wins bullish view at Piper Sandler on cancer therapy
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $9.00 Consensus Target Price from Analysts
Relmada (RLMD) Q4 2025 Earnings Call Transcript
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Earnings Scheduled For March 19, 2026
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
12 Health Care Stocks Moving In Monday's Intraday Session
Why Is Relmada Therapeutics Stock Soaring Monday?
12 Health Care Stocks Moving In Monday's Pre-Market Session
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD)
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology